Nuclear Medicine Radiopharmaceuticals

The Department of Veterans Affairs (VA) Veterans Health Administration, specifically Network Contracting Office 12 (NCO 12) at the Captain James A. Lovell Federal Healthcare Center, is seeking a contract for Nuclear Medicine Radiopharmaceuticals to support diagnostic testing and quality assurance. The solicitation (36C25225Q0339) requires contractors to provide multiple radiopharmaceutical isotopes, with key qualifications including Nuclear Regulatory Commission licensing and compliance with USP 797 guidelines. Contractors must demonstrate capability for routine weekday deliveries three times daily, ability to handle STAT orders within two hours, and provision of comprehensive quality control documentation. The contract opportunity is classified under NAICS code 325412 with a small business size standard of 1,300 employees. Responses are due by March 21, 2025, at 4:00 PM Central Time, with a base year contract period from April 1, 2025, to March 31, 2026.

The solicitation is an unrestricted contract with no specific set-aside designations, allowing broad participation from potential vendors. The contract includes 23 line items for various radiopharmaceutical products such as Tc-99m Ceretec, Tl-201 Thallous Chloride, and Tc-99m Sulfur Colloid, with estimated yearly quantities ranging from 1 to 3,000 units. The place of performance is located in North Chicago, IL 60064, with the contract structured to include the base year and four additional one-year option periods. While specific award values are not detailed in the documentation, the comprehensive list of required isotopes and delivery specifications suggests a potentially significant procurement. The VA's requirement for multiple radiopharmaceutical products indicates a complex and specialized procurement aimed at maintaining high-quality diagnostic capabilities at the federal healthcare center.